% 0期刊文章% Saef依奇%一个Taha Yahya %田曹% Mokalad wa %一个泰国人g . Moreira %霍华德维纳拉斐尔·m . Rezende % % T调节中枢神经系统神经炎症动物模型脑内出血的鼻anti-CD3 (S4.010) % D R 10.1212 / WNL 2023%。0000000000203674 % J首页神经病学% P V 100% N 17补充2% 4001% X目的:探讨鼻治疗的好处anti-CD3治疗我的动物模型。背景:脑内出血(我)是最具破坏性的类型的中风,不成比例的高死亡率接近40%。目前在我治疗的调查主要集中在限制血肿扩张,不幸的是,并没有导致一个有效的治疗方法。在post-ICH继发损伤神经炎症发挥重要作用。接触大脑血液制品薄壁组织发起一个复杂的炎症级联从居民小胶质细胞的激活。循环单核细胞和淋巴细胞产生的细胞因子释放新兵,进一步增强炎症,造成二次伤害。的细胞和分子机制导致神经赤字之后我知之甚少,而且没有有效的疗法来调节缓解中枢神经系统损伤,促进经济复苏。粘膜免疫系统是一个独特的耐受性的器官,它提供了一个生理途径诱导调节性T细胞亚群)。我们发现鼻anti-CD3单克隆抗体诱发IL-10-secreting treg迁移到大脑和抑制小胶质炎症的小鼠模型多发性硬化症。亚/ il - 10的治疗潜力轴我很大程度上是未知的。设计/方法:我们采用胶原酶模型小鼠和管理我的鼻anti-CD3治疗在24小时内我月post-bleed继续了。 We performed Flow cytometry, histopathology and behavioral analyses to characterize the cells and assess the effects of treatment on the behavioral outcomes at 1-month post-ICH.Results: Nasal anti-CD3 increased FoxP3+ Tregs and IL10 producing FoxP3+ Tregs in the brain. It also reduced microglial activation and lesion volume in the ipsilateral hemisphere post-ICH. Treatment improved behavioral outcomes, including motor, spatial learning, and hippocampal-dependent working memory functions at 1-month post-ICH.Conclusions: Our findings suggest that the nasal anti-CD3 may represent a novel therapeutic approach for treating ICH and potentially other types of acute brain injury.Disclosure: Dr. Izzy has received publishing royalties from a publication relating to health care. Taha Yahya has nothing to disclose. Dr. Cao has nothing to disclose. Dr. Waed has nothing to disclose. Dr. Moreira has nothing to disclose. Dr. Rezende has nothing to disclose. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tiziana Life Sciences. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for vTv Therapeutics. Dr. Weiner has received stock or an ownership interest from vTv Therapeutics. The institution of Dr. Weiner has received research support from National Institute of Health. The institution of Dr. Weiner has received research support from National MS Society. The institution of Dr. Weiner has received research support from Genzyme Corp. The institution of Dr. Weiner has received research support from Genentech, Inc. . The institution of Dr. Weiner has received research support from Verily Life Sciences LLC. The institution of Dr. Weiner has received research support from EMD Serono, Inc.. %U